Renin-angiotensin-system blockade in the prevention of diabetes

Diabetes Research and Clinical Practice

Volumn 76, Issue 3 SUPPL., 2007, Pages

  Östergren, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin receptor blockers; Diabetes; Heart failure; Hypertension; Renin angiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TEMOCAPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; INCIDENCE; RANDOMIZED CONTROLLED TRIALS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33947705768     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.018     Document Type: Review

References (40)

1. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
2. Roglic G., Unwin N., Bennett P.H., Mathers C., Tuomilehto J., Naq S., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28 (2005) 2130-2135
3. King H., Aubert R.E., and Herman W.H. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
4. Reaven G.M. Treatment of hypertension: focus on prevention of coronary heart disease. J. Clin. Endocrinol. Metabolism 76 (1993) 537-540
5. Waeber B., Feihl F., and Ruilope L. Diabetes and hypertension. Blood Press 10 (2001) 311-321
6. Gresse T.W., Nieto F.J., Shahar E., Wofford M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N. Engl. J. Med. 342 (2000) 905-912
7. Sowers J.R., Epstein M., and Frohlich E.D. Diabetes, hypertension and cardiovascular disease: an update. Hypertension 37 (2001) 1053-1059
8. Law M.R., Wald N.J., Morris J.K., and Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427-1431
9. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
10. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
11. Stratton I.M., Cull C.A., Adler A., Matthews D.R., Neil H.A., and Holman R.R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49 (2006) 1761-1769
12. Bengtsson C., Blohme G., Lapidus L., Lindquist O., Lundgren H., Nystrom E., et al. Do antihypertensive drugs precipitate diabetes?. BMJ 289 (1984) 1495-1497
13. Lithell H.O. Effects of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14 (1991) 203-209
14. Elliot J.W. Glucose and cholesterol elevations during thiazide therapy: intention-to-treat versus actual on-therapy experience. Am. J. Med. 99 (1995) 216-219
15. Adler A.I. Cardiovascular risk reduction in diabetes: underemphasized and overdue. Messages from major trials. Clin. Med. 1 (2001) 472-477
16. Neutel J.M. Metabolic manifestations of low-dose diuretics. Am. J. Med. 101 Suppl. 3A (1996) S71-S82
17. Julius S., Majahalmes S., and Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am. J. Hypertens. 14 (2001) 310S-316S
18. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64 (2004) 2537-2565
19. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H., et al. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
20. Vermes E., Ducharme A., Bourassa M.G., Lessard M., White M., and Tardif J.-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Circulation 107 (2003) 1291-1296
21. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
22. ALLHAT Officers and Coordinators of the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 107 (2002) 1291-1296
23. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
24. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355 (2006) 1-12
25. Lindholm L.H., Ibsen H., Borsch-Johnsen K., Olsen M.H., Wachtell K., and Dahlof B. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 20 (2002) 1879-1886
26. Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., and Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Evaluation (ALPINE study). J. Hypertens. 21 (2003) 1563-1574
27. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
28. Yusuf S., Ostergren J., Gerstein H.C., Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 (2005) 48-53
29. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21 (2003) 875-886
30. Lund-Johansen P. The role of antihypertensive drugs in countering adverse pathophysiological profiles: influence on hemodynamics. Am. Heart J. 114 (1987) 958-964
31. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J. Hypertens. 24 (2006) 3-10
32. Iimura O., Shimamoto S., Matsuda K., Masuda A., and Takizawa H. Effect of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am. J. Hypertens. 8 (1995) 353-357
33. Higashiuri K., Ura N., Miyazaki Y., and Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resitance and pressor mechanisms in essential hypertension. J. Hum. Hypertens. 13 Suppl. 1 (1999) S71-S74
34. Anan F., Takahashi N., Ooie T., Hara M., Yoshimatsu H., and Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53 (2004) 777-781
35. Grassi G., Seravalle G., Dell'Oro R., Quarti Trevano F., Bombelli M., Scopelliti F., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J. Hypertens. 21 (2003) 1761-1769
36. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
37. Haenni A., Andersson P.E., Lind L., Berne C., and Lithell H. Electrolyte changes and metabolic effects of lisinopril/bendrofluazide: results from a randomized, double-blind study with parallel groups. Am. J. Hypertens. 7 (1994) 615-622
38. Jandeleit-Dahm K.A., Tikellis C., Reid C.M., Johnston C.I., and Cooper M.E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23 (2005) 463-473
39. Kurtz T.W., and Pravenec M. Antidiabetic mechanism of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens. 22 (2004) 2253-2261
40. The Ontarget/transcend Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart. J. 148 (2004) 52-61